{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:54:09Z","timestamp":1789016049776,"version":"build-2803163510"},"reference-count":57,"publisher":"American Association for Cancer Research (AACR)","issue":"23","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"European Union's Horizon 2020","award":["817997"],"award-info":[{"award-number":["817997"]}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Ricerca sul Cancro","doi-asserted-by":"crossref","award":["IG16722"],"award-info":[{"award-number":["IG16722"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Ricerca sul Cancro","doi-asserted-by":"crossref","award":["IG10136"],"award-info":[{"award-number":["IG10136"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Ricerca sul Cancro","doi-asserted-by":"crossref","award":["IG24365"],"award-info":[{"award-number":["IG24365"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Ricerca sul Cancro","doi-asserted-by":"crossref","award":["IG20541"],"award-info":[{"award-number":["IG20541"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA 008748"],"award-info":[{"award-number":["P30 CA 008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA 240139"],"award-info":[{"award-number":["P30 CA 240139"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Multiple myeloma is a biologically heterogenous plasma-cell disorder. In this study, we aimed at dissecting the functional impact on transcriptome of gene mutations, copy-number abnormalities (CNA), and chromosomal rearrangements (CR). Moreover, we applied a geno-transcriptomic approach to identify specific biomarkers for personalized treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>We analyzed 514 newly diagnosed patients from the IA12 release of the CoMMpass study, accounting for mutations in multiple myeloma driver genes, structural variants, copy-number segments, and raw-transcript counts. We performed an in silico drug sensitivity screen (DSS), interrogating the Cancer Dependency Map (DepMap) dataset after anchoring cell lines to primary tumor samples using the Celligner algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Immunoglobulin translocations, hyperdiploidy and chr(1q)gain\/amps were associated with the highest number of deregulated genes. Other CNAs and specific gene mutations had a lower but very distinct impact affecting specific pathways. Many recurrent genes showed a hotspot (HS)-specific effect. The clinical relevance of double-hit multiple myeloma found strong biological bases in our analysis. Biallelic deletions of tumor suppressors and chr(1q)-amplifications showed the greatest impact on gene expression, deregulating pathways related to cell cycle, proliferation, and expression of immunotherapy targets. Moreover, our in silico DSS showed that not only t(11;14) but also chr(1q)gain\/amps and CYLD inactivation predicted differential expression of transcripts of the BCL2 axis and response to venetoclax.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The multiple myeloma genomic architecture and transcriptome have a strict connection, led by CNAs and CRs. Gene mutations impacted especially with HS-mutations of oncogenes and biallelic tumor suppressor gene inactivation. Finally, a comprehensive geno-transcriptomic analysis allows the identification of specific deregulated pathways and candidate biomarkers for personalized treatments in multiple myeloma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1078-0432.ccr-20-4366","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T09:56:05Z","timestamp":1631699765000},"page":"6479-6490","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma"],"prefix":"10.1158","volume":"27","author":[{"given":"Bachisio","family":"Ziccheddu","sequence":"first","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy."},{"name":"2Multiple Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-6584","authenticated-orcid":false,"given":"Matteo C.","family":"Da Vi\u00e0","sequence":"additional","affiliation":[{"name":"3Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy."},{"name":"4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-9095","authenticated-orcid":false,"given":"Marta","family":"Lionetti","sequence":"additional","affiliation":[{"name":"3Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy."},{"name":"4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Maeda","sequence":"additional","affiliation":[{"name":"4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morlupi","sequence":"additional","affiliation":[{"name":"4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Dugo","sequence":"additional","affiliation":[{"name":"5Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Todoerti","sequence":"additional","affiliation":[{"name":"3Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy."},{"name":"4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Oliva","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"D'Agostino","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."},{"name":"6Department of Clinical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"2Multiple Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida."},{"name":"7Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"8Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7063-8913","authenticated-orcid":false,"given":"Francesco","family":"Iorio","sequence":"additional","affiliation":[{"name":"9Centre for Computational Biology, Human Technopole, Milan, Italy."},{"name":"10Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Pettine","sequence":"additional","affiliation":[{"name":"3Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pompa","sequence":"additional","affiliation":[{"name":"3Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0861-9951","authenticated-orcid":false,"given":"Martina","family":"Manzoni","sequence":"additional","affiliation":[{"name":"3Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy."},{"name":"4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Baldini","sequence":"additional","affiliation":[{"name":"3Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy."},{"name":"4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[{"name":"3Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy."},{"name":"4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[{"name":"2Multiple Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida."},{"name":"7Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"8Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1018-5139","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Bolli","sequence":"additional","affiliation":[{"name":"3Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy."},{"name":"4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"2024112516463439900_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2024112516463439900_bib2","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","article-title":"Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing","volume":"26","author":"D'Agostino","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2024112516463439900_bib3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"key":"2024112516463439900_bib4","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.20.00461","article-title":"Genome-wide somatic alterations in multiple myeloma reveal a Superior Outcome Group","volume":"38","author":"Samur","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024112516463439900_bib5","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1097\/HS9.0000000000000502","article-title":"A journey through myeloma evolution: From the normal plasma cell to disease complexity","volume":"4","author":"Da Via","year":"2020","journal-title":"Hemasphere"},{"key":"2024112516463439900_bib6","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"key":"2024112516463439900_bib7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/bloodadvances.2019000779","article-title":"Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma","volume":"4","author":"Ziccheddu","year":"2020","journal-title":"Blood Adv"},{"key":"2024112516463439900_bib8","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"key":"2024112516463439900_bib9","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome instability in multiple myeloma","volume":"34","author":"Neuse","year":"2020","journal-title":"Leukemia"},{"key":"2024112516463439900_bib10","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"key":"2024112516463439900_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"2024112516463439900_bib12","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"2024112516463439900_bib13","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"key":"2024112516463439900_bib14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"2024112516463439900_bib15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"2024112516463439900_bib16","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/sj.onc.1208447","article-title":"Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma","volume":"24","author":"Mattioli","year":"2005","journal-title":"Oncogene"},{"key":"2024112516463439900_bib17","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2024112516463439900_bib18","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41467-017-00638-w","article-title":"Expressed fusion gene landscape and its impact in multiple myeloma","volume":"8","author":"Cleynen","year":"2017","journal-title":"Nat Commun"},{"key":"2024112516463439900_bib19","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1038\/s41467-020-16434-y","article-title":"Evolution and structure of clinically relevant gene fusions in multiple myeloma","volume":"11","author":"Foltz","year":"2020","journal-title":"Nat Commun"},{"key":"2024112516463439900_bib20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/leu.2017.197","article-title":"Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma","volume":"32","author":"Lagana","year":"2018","journal-title":"Leukemia"},{"key":"2024112516463439900_bib21","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2014-04-569327","article-title":"Differential and limited expression of mutant alleles in multiple myeloma","volume":"124","author":"Rashid","year":"2014","journal-title":"Blood"},{"key":"2024112516463439900_bib22","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"2024112516463439900_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fonc.2020.00189","article-title":"Next-generation sequencing for clinical management of multiple myeloma: Ready for prime time?","volume":"10","author":"Bolli","year":"2020","journal-title":"Front Oncol"},{"key":"2024112516463439900_bib24","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1038\/bcj.2016.72","article-title":"A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma","volume":"6","author":"Bolli","year":"2016","journal-title":"Blood Cancer J"},{"key":"2024112516463439900_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-019-0264-y","article-title":"Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma","volume":"9","author":"Yellapantula","year":"2019","journal-title":"Blood Cancer J"},{"key":"2024112516463439900_bib26","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2024112516463439900_bib27","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: Precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol"},{"key":"2024112516463439900_bib28","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol"},{"key":"2024112516463439900_bib29","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1038\/ncomms6901","article-title":"Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes","volume":"6","author":"Gerstung","year":"2015","journal-title":"Nat Commun"},{"key":"2024112516463439900_bib30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nbt.3391","article-title":"Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity","volume":"34","author":"Chang","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2024112516463439900_bib31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"2024112516463439900_bib32","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024112516463439900_bib33","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A Landscape of Pharmacogenomic Interactions in Cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"2024112516463439900_bib34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"2024112516463439900_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41467-020-20294-x","article-title":"Global computational alignment of tumor and cell line transcriptional profiles","volume":"12","author":"Warren","year":"2021","journal-title":"Nat Commun"},{"key":"2024112516463439900_bib36","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1200\/JCO.2005.01.3870","article-title":"Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations","volume":"23","author":"Agnelli","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024112516463439900_bib37","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1182\/blood-2011-10-388702","article-title":"Prediction of cytogenetic abnormalities with gene expression profiles","volume":"119","author":"Zhou","year":"2012","journal-title":"Blood"},{"key":"2024112516463439900_bib38","doi-asserted-by":"crossref","first-page":"26129","DOI":"10.18632\/oncotarget.4674","article-title":"A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias","volume":"6","author":"Lionetti","year":"2015","journal-title":"Oncotarget"},{"key":"2024112516463439900_bib39","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood.2019000080","article-title":"Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness","volume":"134","author":"Munawar","year":"2019","journal-title":"Blood"},{"key":"2024112516463439900_bib40","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3324\/haematol.2019.239913","article-title":"Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression","volume":"106","author":"Solimando","year":"2021","journal-title":"Haematologica"},{"key":"2024112516463439900_bib41","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1182\/blood.2019000578","article-title":"PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation","volume":"134","author":"Ren","year":"2019","journal-title":"Blood"},{"key":"2024112516463439900_bib42","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"2024112516463439900_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/leu.2013.174","article-title":"Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications","volume":"28","author":"Bjorklund","year":"2014","journal-title":"Leukemia"},{"key":"2024112516463439900_bib44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"2024112516463439900_bib45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2024112516463439900_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"2024112516463439900_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8509","article-title":"Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume-title":"J Clin Oncol","author":"Kumar","year":"2020"},{"key":"2024112516463439900_bib48","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","article-title":"Targeting Bcl-2 for the treatment of multiple myeloma","volume":"32","author":"Touzeau","year":"2018","journal-title":"Leukemia"},{"key":"2024112516463439900_bib49","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1084\/jem.20070318","article-title":"Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD","volume":"204","author":"Hovelmeyer","year":"2007","journal-title":"J Exp Med"},{"key":"2024112516463439900_bib50","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"key":"2024112516463439900_bib51","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"2024112516463439900_bib52","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41419-020-2505-1","article-title":"Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX\/BAK hetero-complexes","volume":"11","author":"Seiller","year":"2020","journal-title":"Cell Death Dis"},{"key":"2024112516463439900_bib53","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41375-019-0689-0","article-title":"Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma","volume":"34","author":"Maura","year":"2020","journal-title":"Leukemia"},{"key":"2024112516463439900_bib54","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv"},{"key":"2024112516463439900_bib55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"key":"2024112516463439900_bib56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"2024112516463439900_bib57","doi-asserted-by":"crossref","unstructured":"Neri\u2008P, Maity\u2008R, Alberge\u2008J, Sinha\u2008S, Donovan\u2008J, Kong\u2008M, et al\u2008Mutations and copy number gains of the BCL2 family members mediate resistance to venetoclax in multiple myeloma (MM) patients. In: Proceedings of the American Society of Hematology Annual meeting; 2019; San Diego, CA. Blood;\u20082019.","DOI":"10.1182\/blood-2019-127593"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/27\/23\/6479\/3522354\/6479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/27\/23\/6479\/3522354\/6479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T11:47:17Z","timestamp":1732535237000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/27\/23\/6479\/674995\/Functional-Impact-of-Genomic-Complexity-on-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":57,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12,1]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-4366","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1078-0432.27902396","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.27902390","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.27902393","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.c.7555712","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}